Rybrevant with Leclaza Shows Significantly Improved Progression-Free Survival vs. Tagrisso Treating EGFR-Mutated Advanced NSCLC
Image credit: Sebastian Kaulitzki | stock.adobe.com The combination of Rybrevant (amivantamab-vmjw; Janssen Pharmaceutical) with Leclaza (lazertinib; Johnson & Johnson) produced…